INS and Obesity: Recent studies indicated that THCV-CB1 receptor antagonists/inverse agonists ameliorated insulin sensitivity and improved glucose tolerance in two mouse models of obesity [18], reduced accumulated lipid levels in vitro in a hepatosteatosis model and in adipocytes [19], and decreased fasting plasma glucose with improved pancreatic β-cell function in a randomized, double-blind, placebo-controlled study on type 2 diabetes [20].